Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-rhabdomyosarcoma Clear all
Completed Not applicable Interventional

Caspofungin Acetate in Treating Children With Fever and Neutropenia

NCT00020527
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Kidney Cancer, Leukemia, Lymphoma, Neuroblastoma, Neutropenia, Sarcoma
Interventions
caspofungin acetate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00079222
View directory record Official record
Conditions
Cancer
Interventions
itraconazole, voriconazole
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jul 23, 2026, 11:41 PM EDT
Recruiting No phase listed Observational

Molecular Analysis Of Solid Tumors

NCT01050296
View directory record Official record
Conditions
Pediatric Solid Tumors
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 25 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 23, 2026, 11:41 PM EDT
Terminated Phase 2 Interventional Results available

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

NCT02624388
View directory record Official record
Conditions
Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor, Neuroblastoma, Ewing Sarcoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Medulloblastoma, Germ Cell Tumor, Wilms Tumor, Brain Neoplasms, Medulloblastoma, Childhood, Neuroectodermal Tumors, Primitive
Interventions
Genistein, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
1 Year to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 1 Interventional

Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors

NCT00002543
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
gallium nitrate
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 1 Interventional

Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

NCT00638898
View directory record Official record
Conditions
Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Ovarian Mixed Germ Cell Tumor, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Adult Brain Tumor, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Neuroblastoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
busulfan, melphalan, topotecan hydrochloride, laboratory biomarker analysis, filgrastim, autologous hematopoietic stem cell transplantation, pharmacological study, autologous bone marrow transplantation
Drug · Other · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
6 Months to 40 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

NCT00509691
View directory record Official record
Conditions
Cancer
Interventions
cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis, flow cytometry, immunologic technique
Biological · Genetic · Other
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 2 Interventional

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

NCT00006102
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
becatecarin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
198
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 2 Interventional

Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas

NCT00165139
View directory record Official record
Conditions
Neuroblastoma, Ewings Sarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma
Interventions
Vincristine, Cyclophosphamide, Adriamycin, Etoposide (VP-16), Cisplatin, Carboplatin, Melphalan, Ifosfamide, G-CSF (granulocyte-colony stimulating factor), Mesna
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 19 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2009 · Synced Jul 23, 2026, 11:41 PM EDT
Active, not recruiting Phase 2 Interventional

Methionine PET/CT Studies In Patients With Cancer

NCT00840047
View directory record Official record
Conditions
Brain Tumors and/or Solid Tumors Including, Brain Stem Glioma, High Grade CNS Tumors, Ependymoma, Medulloblastoma, Craniopharyngioma, Low Grade CNS Tumors, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Other
Interventions
Methionine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer

NCT00002515
View directory record Official record
Conditions
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, thiotepa, topotecan hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support, in vitro-treated bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

Molecular-Guided Therapy for Childhood Cancer

NCT02162732
View directory record Official record
Conditions
Neuroblastoma, Medulloblastoma, Glioma, Ependymoma, Choroid Plexus Neoplasms, Craniopharyngioma, Dysembryoplastic Neuroepithelial Tumor, Meningioma, Primitive Neuroectodermal Tumors (PNETs), Germ Cell Tumors, Rhabdomyosarcoma, Non-rhabdomyosarcoma, Ewings Sarcoma, Osteosarcoma, Wilms Tumor, Renal Cell Carcinoma, Malignant Rhabdoid Tumor, Clear Cell Sarcoma, Liver Tumors
Interventions
Guided Therapy
Device
Lead sponsor
Giselle Sholler
Other
Eligibility
13 Months to 21 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
18
States / cities
Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Jul 23, 2026, 11:41 PM EDT
Withdrawn No phase listed Observational

Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant

NCT00898612
View directory record Official record
Conditions
Lymphoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 3 Interventional

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

NCT00014391
View directory record Official record
Conditions
Cancer
Interventions
palivizumab, ribavirin
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

NCT02095132
View directory record Official record
Conditions
Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered, Pineoblastoma, Primary Central Nervous System Neoplasm, Recurrent Childhood Central Nervous System Embryonal Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
Interventions
Adavosertib, Irinotecan Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Jul 23, 2026, 11:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
168
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Not listed Phase 2 Interventional

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

NCT00084695
View directory record Official record
Conditions
Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, melphalan, methylprednisolone, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Jul 23, 2026, 11:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

NCT03458728
View directory record Official record
Conditions
Relapsed or Refractory Solid Tumors or Lymphoma in Children, Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma
Interventions
Copanlisib (BAY806946)
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Birmingham, Alabama • Orange, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 1 Interventional

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

NCT01625351
View directory record Official record
Conditions
Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor, Lymphoma, Wilms Tumor, Rhabdoid Tumor, Clear Cell Carcinoma, Renal Cell Carcinoma, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma
Interventions
alemtuzumab, fludarabine, sirolimus, Busulfan, melphalan, stem cells, CliniMACS
Drug · Biological · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas

NCT00592293
View directory record Official record
Conditions
Non-rhabdomyosarcoma Soft Tissue Sarcoma, Bone Sarcoma
Interventions
Proton Beam Radiation
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Up to 30 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

NCT03213678
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Malignant Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Samotolisib, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
125
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Recruiting Phase 1 Interventional

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

NCT07148050
View directory record Official record
Conditions
Solid Tumor (Excluding CNS), Liver Cell Carcinoma, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Liposarcoma, Rhabdomyosarcoma, Embryonal Sarcoma of Liver, Wilms Tumor, Hepatocellular Carcinoma, Hepatoblastoma
Interventions
SC-CAR.GPC3xIL15.21 CAR T cells
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 26 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Not listed Not applicable Interventional

Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma

NCT00072488
View directory record Official record
Conditions
Lymphoma, Neuroblastoma, Sarcoma
Interventions
computed tomography, magnetic resonance imaging, positron emission tomography
Procedure
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
Up to 21 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
17
States / cities
San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2010 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 1 Interventional

Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy

NCT00030108
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Leukemia, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ixabepilone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
2 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jul 23, 2026, 11:41 PM EDT